Sage Therapeutics

Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics for $8.50 per share upfront plus contingent payments up to $3.50 per share, totaling up to $795 million.

Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for up to $795 million, offering $8.50 per share in cash plus contingent value rights worth $3.50 per share based on sales milestones.

Ellipsis Health secured $45 million in Series A funding led by Salesforce, Khosla Ventures, and CVS Health Ventures to advance AI-powered care management solutions.

A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.

SageMedic Corp. is presenting its SAGE Oncotest™, an ex-vivo 3D microtumor assay that evaluates live tumor tissue responses to FDA-approved therapies, at the AACR Annual Meeting in Chicago.

• Sage Therapeutics and Biogen's SAGE-324 shows no significant benefit in Phase II KINETIC 2 study for essential tremor treatment. • Jazz Pharmaceuticals experiences setback as suvecaltamide fails to meet primary and key secondary endpoints in Phase IIb essential tremor trial. • Recent trial failures highlight ongoing challenges in developing effective treatments for essential tremor, a condition affecting millions worldwide.

• Biogen approaches Q4 earnings with Wall Street projecting $3.35 adjusted EPS and $2.40 billion in sales, while facing challenges in Leqembi adoption and market penetration. • FDA approved Leqembi's new maintenance dosing schedule for Alzheimer's disease, allowing four-week intervals after initial bi-weekly treatment phase. • European regulatory developments and higher dose nusinersen applications for SMA highlight Biogen's expanding therapeutic portfolio despite market headwinds.

Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development.

• Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations to support its Phase 3 program for oral levosimendan (TNX-103). • Ms. Andor brings over 20 years of experience in clinical operations, including NDA submissions and approvals, to accelerate the Phase 3 LEVEL study. • Her expertise will be crucial as Tenax Therapeutics advances oral levosimendan for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). • The appointment signifies Tenax's commitment to strengthening its clinical development capabilities as it prepares for potential global regulatory filings.

• A new report offers an overview of the clinical trial landscape for Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy, providing key data and analysis. • The review includes data on trial numbers, average enrollment, and top countries involved, segmented by region, phase, status, endpoints, and sponsor type. • Key companies like Jazz Pharmaceuticals, UCB, Takeda, and others are profiled, with details on their ongoing trials and prominent drugs in development for Dravet Syndrome. • The report identifies trends in clinical trial enrollment over the past five years and highlights recent news related to Dravet Syndrome research and development.